Where it trades today
trading 79% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- BMY trades at 13.9x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- BMY carries a beta of 0.23, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- BMY is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for BMY come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for BMY. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Bristol-Myers Squibb does
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of…
Employees
32,500
Industry
Drug Manufacturers - General
Headquarters
Princeton, United States
What analysts expect
BMY carries a buy consensus from 24 analysts, with an average price target of $66.71 versus $63.06 today (+5.8%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
BMY generated $49.19B in trailing revenue (5.7% year over year), with a 18.9% net margin, and $8.11B of free cash flow, against $33.99B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $48.20B | $34.26B | $13.72B | $7.05B | $3.47 | $12.85B |
| 2024 | $48.30B | $34.33B | $5.89B | -$8.95B | -$4.41 | $13.94B |
| 2023 | $45.01B | $34.31B | $8.20B | $8.03B | $3.88 | $12.65B |
| 2022 | $46.16B | $36.02B | $9.10B | $6.33B | $2.97 | $11.95B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
BMY beside the healthcare names it is usually measured against.
What the chart is saying
Bristol-Myers Squibb trades at $63.06, 8.1% below its 52-week high. With a beta of 0.23, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is BMY a good buy right now?
Bristol-Myers Squibb trades at 13.9x earnings. This is below market average, potentially undervalued. Current risk level is Medium based on 21.9% volatility.
Does BMY pay dividends?
Yes, Bristol-Myers Squibb offers a dividend yield of 4.01%. That is roughly $2.53 per share a year.
How volatile is BMY?
With 30-day annualized volatility of 21.9% and beta of 0.23, BMY is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for BMY?
The average analyst price target for Bristol-Myers Squibb (BMY) is $66.71 based on 24 analyst estimates, about 5.8% above the current price of $63.06. The published range runs from $40.00 to $82.00.
How much revenue does BMY generate?
Bristol-Myers Squibb reported $49.19B in trailing twelve-month revenue. Revenue growth is running at 5.7% year over year. Net margin sits at 18.9%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.